Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
ANNX submitted a Form 144 notice relating to 5,565 common shares associated with Fidelity Brokerage Services LLC, with a record row showing 03/02/2026 and NASDAQ.
The filing also lists a restricted stock vesting event dated 02/27/2026 tied to 5,565 shares (labeled "Compensation"), and a prior sale by Jennifer Lew of 7,851 common shares on 02/18/2026 with an adjacent figure of 40119.40.
Love Douglas reported acquisition or exercise transactions in this Form 4 filing.
Annexon, Inc. director and President & CEO Douglas Love reported receiving a grant of stock options covering 1,250,000 shares of the company’s stock. These are derivative securities, reflecting an equity incentive award rather than an open-market share purchase or sale.
According to the vesting terms, 1/48th of the option shares vest on each monthly anniversary starting on February 19, 2026, so the award becomes fully vested and exercisable on the fourth anniversary of that date. Vesting depends on Mr. Love’s continuous service with Annexon on each vesting date.
Annexon, Inc. reported that its Chief Medical Officer, Jamie Dananberg, received new equity awards on February 19, 2026. The awards include a stock option covering 225,000 shares at an exercise price of $0.00 per share and a grant of 56,250 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, 1/48 of the option shares vest monthly starting from February 19, 2026, becoming fully vested on the fourth anniversary, subject to continued service. For the RSUs, one-third vests each year on February 19, with the first third vesting on February 19, 2027, also conditioned on continuous service. Following these grants, Dananberg directly owns 129,402 shares of common stock.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported equity awards consisting of stock options and restricted stock units. He was granted 250,000 stock options at an exercise price of $0.00 per share, with 1/48th of the option vesting monthly from February 19, 2026 so that all options vest over four years, subject to continued service. He also received 62,500 RSUs, each convertible into one share of common stock, with 1/3 vesting each year on February 19 starting in 2027, also conditioned on continued service.
Annexon, Inc. reported that EVP & Chief Scientific Officer Dean Richard Artis acquired equity awards on February 19, 2026. He received a stock option for 250,000 shares at an exercise price of $0.00 per share and 62,500 restricted stock units. The RSUs vest one-third each year on February 19, beginning in 2027, while 1/48 of the option vests monthly from February 19, 2026, becoming fully vested on the fourth anniversary, subject to his continuous service.
Annexon, Inc. reported that EVP & Chief Innovation Officer Ted Yednock acquired new equity awards. He received a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting on February 19, 2026.
He also received 62,500 restricted stock units, each RSU converting into one share of common stock upon vesting. One-third of these RSUs vest annually on February 19 of each year, with the first one-third vesting on February 19, 2027, subject to his continued service with the company.
Annexon, Inc. reported that EVP and Chief Financial Officer Jennifer Lew received equity awards on February 19, 2026. She was granted a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting from February 19, 2026. She also received 62,500 shares of common stock in the form of restricted stock units, each RSU representing one share upon vesting. One-third of these RSUs vest on February 19 of each year, with the first third vesting on February 19, 2027, subject to her continued service with the company.
Annexon, Inc. chief medical officer Jamie Dananberg reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related sale, Dananberg directly holds 73,152 Annexon shares.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 7,851 shares of common stock at a weighted average price of $5.11 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, she directly holds 113,765 shares of Annexon common stock.
Annexon, Inc. executive reports tax-related stock sale
Annexon, Inc. executive Dean Richard Artis, EVP & Chief Scientific Officer, reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the filing, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, Artis beneficially owns 123,487 shares of Annexon common stock directly. The sale was executed in multiple trades within a price range of $4.925 to $5.155 per share.